Medical devices tenders in Estonia.

Over the last 120 days, Estonia’s medical device market recorded around 360 announced RHR tenders in CPV division 33. Announced value was EUR 204.2M. Activity is cooling, down 26% from the preceding period, with around 90 tenders monthly and around 21 weekly.

The median announced tender value is EUR 259K, which better represents a typical opportunity than the EUR 954K average. The gap shows a strongly right skewed market, where a small number of major procurements raise total and average values well above the usual opportunity.

Buying is concentrated among hospitals. The five largest buyers account for 66% of disclosed value. Key accounts include Tartu University Hospital, Ida Tallinn Central Hospital, Põhja Eesti Regional Hospital, Lääne Tallinn Central Hospital and Tallinn Children’s Hospital. This is buyer concentration, not winner concentration, so hospital account coverage is central.

The market brief does not provide a standard preparation period or deadline length. It does show why speed matters: activity peaked at around 120 tenders in April 2026, then fell to around 60 in May and June and around 30 in July. Suppliers should monitor RHR frequently and assess each notice’s own deadline.

The supplied data does not identify the share of foreign winners or set out cross border eligibility rules. It does show an official public procurement route through RHR and a market served by many specialist winners. Foreign suppliers should therefore verify the requirements, language, documentation and eligibility conditions in each published notice.

Yes, the market appears newcomer friendly, although no result is guaranteed. Seventy six percent of winners took exactly one contract during the period. That pattern indicates room for specialist suppliers to enter through an individual lot or smaller procurement, rather than depending only on the largest tenders.

Estonia’s official public procurement portal is RHR. Suppliers looking for medical device opportunities should use that portal and search within CPV division 33, while checking the full notice and procurement documents for scope, qualification requirements, lots, deadlines and submission instructions. The market brief covers announcements from the last 120 days.

Competition is meaningful but not dominated by a few repeat winners. The data identifies 29 winning companies, and 76% of winners took exactly one contract. The highest disclosed winner values include EUR 11.6M for Apteegikaubanduse Hulgimüük OÜ and EUR 3.3M for Nutrimedical OÜ, but buyer concentration should not be confused with winner concentration.

Use a two part approach. First, build focused relationships and monitoring around the dominant hospital buyers, because the top five account for 66% of disclosed value. Second, maintain a broad bid strategy for median sized opportunities, since EUR 259K is the median and 76% of winners took exactly one contract.

Based on this market brief, Otnox can help suppliers apply a focused monitoring strategy: follow RHR notices in CPV division 33, prioritise the hospitals responsible for most disclosed value, and surface median sized opportunities. This matches the recommended combination of hospital engagement and broad bidding. The brief does not specify additional Otnox features.